优化Baveno VI瞬时弹性成像标准定义代偿期进展性慢性肝病
这项多中心研究纳入5648例有肝活检和瞬时弹性成像的患者,验证Baveno VI的<10和>15 kPa双切点,发现<7和>12 kPa双切点诊断代偿期进展性慢性肝病(cACLD)的准确性更优(AUC 0.87),酒精性肝病和非酒精性脂肪性肝病可用<8 kPa低切点。
要点
- Baveno VI的<10和>15 kPa双切点排除和诊断cACLD的敏感性分别为75%和特异性96%。
- <7和>12 kPa双切点排除和诊断cACLD的敏感性91%、特异性92%(AUC 0.87)。
- 酒精性肝病和非酒精性脂肪性肝病低切点可用8 kPa(敏感性93%)。
核心结论
- 相比Baveno VI的<10和>15 kPa双切点,<8 kPa(病毒性肝炎<7 kPa)和>12 kPa双切点在诊断cACLD时具有更好的诊断准确性。
研究设计与样本
- 研究纳入来自10个欧洲肝病中心的5648例患者(平均年龄51±13岁,53%男性),均在6个月内接受肝活检和瞬时弹性成像测量。
- 患者包括慢性丙型肝炎2913例(52%)、非酒精性脂肪性肝病1073例(19%)、酒精性肝病946例(17%)和慢性乙型肝炎716例(13%)。
- cACLD定义为纤维化分期≥F3。
主要发现
- 总体中,3606例(66%)患者LS<10 kPa,987例(18%)患者LS>15 kPa,组织学确诊cACLD者1772例(31%)。
- LS<10和>15 kPa切点排除和诊断cACLD的敏感性分别为75%和特异性96%。
- ROC曲线分析得出更优双切点<7和>12 kPa,排除和诊断cACLD的敏感性91%、特异性92%(AUC 0.87;95%CI 0.86-0.88;p<0.001)。
- 对于酒精性肝病和非酒精性脂肪性肝病,低切点可用8 kPa(敏感性93%)。
- 对于未分类患者,基于常见患者特征推导的风险模型判别能力优于单独LS(AUC 0.74 vs. 0.69;p<0.001)。
关键数值与推荐
- Baveno VI推荐LS<10 kPa排除cACLD、>15 kPa诊断cACLD(敏感性75%、特异性96%)。
- 研究推导的双切点<7和>12 kPa排除和诊断cACLD的敏感性91%、特异性92%(AUC 0.87)。
- 酒精性肝病和非酒精性脂肪性肝病低切点可用8 kPa(敏感性93%)。
临床怎么用
- 临床可考虑用<8 kPa(病毒性肝炎<7 kPa)和>12 kPa双切点替代Baveno VI的<10和>15 kPa标准,以提高cACLD诊断准确性。
- 对酒精性肝病和非酒精性脂肪性肝病患者,低切点可选用8 kPa(敏感性93%)。
- 对未分类患者,可结合基于常见患者特征的风险模型提升判别能力(AUC 0.74 vs. 0.69)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Baveno VI consensus proposed a dual liver stiffness (LS) by transient elastography threshold of <10 and >15 kPa for excluding and diagnosing compensated advanced chronic liver disease (cACLD) in the absence of other clinical signs. Herein, we aimed to validate these criteria in a real-world multicentre study. METHODS: We included 5,648 patients (mean age 51 ± 13 years, 53% males) from 10 European liver centres who had a liver biopsy and LS measurement within 6 months. We included patients with chronic hepatitis C (n = 2,913, 52%), non-alcoholic fatty liver disease (NAFLD, n = 1,073, 19%), alcohol-related liver disease (ALD, n = 946, 17%) or chronic hepatitis B (n = 716, 13%). cACLD was defined as fibrosis stage ≥F3. RESULTS: Overall, 3,606 (66%) and 987 (18%) patients had LS <10 and >15 kPa, respectively, while cACLD was histologically confirmed in 1,772 (31%) patients. The cut-offs of <10 and >15 kPa showed 75% sensitivity and 96% specificity to exclude and diagnose cACLD, respectively. Examining the ROC curve, a more optimal dual cut-off at <7 and >12 kPa, with 91% sensitivity and 92% specificity for excluding and diagnosing cACLD (AUC 0.87; 95% CI 0.86-0.88; p <0.001) was derived. Specifically, for ALD and NAFLD, a low cut-off of 8 kPa can be used (sensitivity=93%). For the unclassified patients, we derived a risk model based on common patient characteristics with better discrimination than LS alone (AUC 0.74 vs. 0.69; p <0.001). CONCLUSIONS: Instead of the Baveno VI proposed <10 and >15 kPa dual cut-offs, we found that the <8 kPa (or <7 kPa for viral hepatitis) and >12 kPa dual cut-offs have better diagnostic accuracy in cACLD. LAY SUMMARY: The term compensated advanced chronic liver disease (cACLD) was introduced in 2015 to describe the spectrum of advanced fibrosis and cirrhosis in asymptomatic patients. It was also suggested that cACLD could be diagnosed or ruled out based on specific liver stiffness values, which can be non-invasively measured by transient elastography. Herein, we assessed the suggested cut-off values and identified alternative values that offered better overall accuracy for diagnosing or ruling out cACLD.
引用
- Papatheodoridi M, Hiriart JB, Lupsor-Platon M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2020. PMID: 33307138. doi:10.1016/j.jhep.2020.11.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。